

# FOLOTYN - pralatrexate injection

## Acrotech Biopharma Inc

-----

### HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use FOLOTYN® safely and effectively. See full prescribing information for FOLOTYN.

**FOLOTYN (pralatrexate injection), for intravenous use**  
**Initial U.S. Approval: 2009**

### INDICATIONS AND USAGE

FOLOTYN is a dihydrofolate reductase inhibitor indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).

This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). (1)

### DOSAGE AND ADMINISTRATION

- Supplement patients with vitamin B<sub>12</sub> mg intramuscularly every 8-10 weeks starting 10 weeks before the first dose and folic acid 1 to 1.25 mg orally once daily starting 10 days before the first dose. (2.1)
- The recommended dosage of FOLOTYN is 30 mg/m<sup>2</sup> intravenously over 3 to 5 minutes once weekly for 6 weeks in 7-week cycles. (2.1)
- For patients with severe renal impairment (GFR 15 to 29 mL/min/1.73 m<sup>2</sup>), reduce the FOLOTYN dose to 15 mg/m<sup>2</sup> (2.1).

### DOSAGE FORMS AND STRENGTHS

Injection: 20 mg/1 mL or 40 mg/2 mL in a single-dose vial (3)

### CONTRAINDICATIONS

None.(4)

### WARNINGS AND PRECAUTIONS

- Myelosuppression: Monitor complete blood counts and omit and/or reduce dose based on ANC and platelet count. (2.4, 5.1)
- Mucositis: Monitor at least weekly. Omit and/or reduce dose for grade 2 or higher mucositis. (2.4, 5.2)
- Dermatologic reactions: Reactions, including fatal reactions, occurred and may be progressive and increase in severity with further treatment. Monitor closely and withhold or discontinue FOLOTYN based on severity. (2.4, 5.3)
- Tumor lysis syndrome: Monitor patients who are increased risk and treat promptly. (5.4)
- Hepatic toxicity: Monitor for liver function tests. Omit until recovery, adjust or discontinue therapy based on severity. (2.4, 5.5)
- Risk of increased toxicity with renal impairment: Avoid FOLOTYN in patients with end stage renal disease with or without dialysis. If the potential benefit of administration justifies the potential risk, monitor renal function and reduce the FOLOTYN dose based on adverse reactions. (2.3, 2.4, 5.6)
- Embryo-fetal toxicity: Can cause fetal harm. Advise patients of the potential risk to a fetus and to use an effective method of contraception. (5.7, 8.1, 8.3)

### ADVERSE REACTIONS

Most common adverse reactions (>35%) are mucositis, thrombocytopenia, nausea, and fatigue. (6.1)

**To report SUSPECTED ADVERSE REACTIONS, contact Acrotech Biopharma Inc at 1-888-255-6788 or [www.FOLOTYN.com](http://www.FOLOTYN.com) or FDA at 1-800-FDA-1088 or [www.fda.gov/medwatch](http://www.fda.gov/medwatch)**

### DRUG INTERACTIONS

- Avoid coadministration with probenecid or nonsteroidal anti-inflammatory drugs. If coadministration is unavoidable, monitor for increased risk of adverse reactions. (7.1)

### USE IN SPECIFIC POPULATIONS

- Lactation: Advise not to breastfeed. (8.2)

**See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.**

**Revised: 6/2023**

---

## **FULL PRESCRIBING INFORMATION: CONTENTS\***

### **1 INDICATIONS AND USAGE**

### **2 DOSAGE AND ADMINISTRATION**

- 2.1 Important Dosing Information
- 2.2 Recommended Dosage
- 2.3 Dosage Modifications for Renal Impairment and End Stage Renal Disease
- 2.4 Monitoring and Dosage Modifications for Adverse Reactions
- 2.5 Preparation and Administration

### **3 DOSAGE FORMS AND STRENGTHS**

### **4 CONTRAINDICATIONS**

### **5 WARNINGS AND PRECAUTIONS**

- 5.1 Myelosuppression
- 5.2 Mucositis
- 5.3 Dermatologic Reactions
- 5.4 Tumor Lysis Syndrome
- 5.5 Hepatic Toxicity
- 5.6 Risk of Increased Toxicity with Renal Impairment
- 5.7 Embryo-Fetal Toxicity

### **6 ADVERSE REACTIONS**

- 6.1 Clinical Trials Experience
- 6.2 Postmarketing Experience

### **7 DRUG INTERACTIONS**

- 7.1 Effects of Other Drugs on FOLOTYN

### **8 USE IN SPECIFIC POPULATIONS**

- 8.1 Pregnancy
- 8.2 Lactation
- 8.3 Females and Males of Reproductive Potential
- 8.4 Pediatric Use
- 8.5 Geriatric Use
- 8.6 Renal Impairment

### **10 OVERDOSAGE**

### **11 DESCRIPTION**

### **12 CLINICAL PHARMACOLOGY**

- 12.1 Mechanism of Action
- 12.2 Pharmacodynamics
- 12.3 Pharmacokinetics

### **13 NONCLINICAL TOXICOLOGY**

- 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

### **14 CLINICAL STUDIES**

### **15 REFERENCES**

### **16 HOW SUPPLIED/STORAGE AND HANDLING**

### **17 PATIENT COUNSELING INFORMATION**

\* Sections or subsections omitted from the full prescribing information are not listed.

---

## **FULL PRESCRIBING INFORMATION**

### **1 INDICATIONS AND USAGE**

FOLOTYN is indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).

This indication is approved under accelerated approval based on overall response rate [see *Clinical Studies (14)*]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

### **2 DOSAGE AND ADMINISTRATION**

#### **2.1 Important Dosing Information**

##### Pretreatment Vitamin Supplementation

###### *Folic Acid*

Instruct patients to take folic acid 1 to 1.25 mg orally once daily beginning 10 days before the first dose of FOLOTYN. Continue folic acid during treatment with FOLOTYN and for 30 days after the last dose [see *Warnings and Precautions (5.1, 5.2)*].

###### *Vitamin B<sub>12</sub>*

Administer vitamin B<sub>12</sub> 1 mg intramuscularly within 10 weeks prior to the first dose of FOLOTYN and every 8-10 weeks thereafter. Subsequent vitamin B<sub>12</sub> injections may be given the same day as treatment with FOLOTYN [see *Warnings and Precautions (5.1, 5.2)*].

#### **2.2 Recommended Dosage**

The recommended dosage of FOLOTYN is 30 mg/m<sup>2</sup> intravenously over 3-5 minutes once weekly for 6 weeks in 7-week cycles until progressive disease or unacceptable toxicity.

#### **2.3 Dosage Modifications for Renal Impairment and End Stage Renal Disease**

- Severe renal impairment (eGFR 15 to 29 mL/min/1.73 m<sup>2</sup> by MDRD): Reduce the FOLOTYN dose to 15 mg/m<sup>2</sup> [see *Use in Specific Populations (8.6)*].
- End stage renal disease (ESRD: eGFR less than 15 mL/min/1.73 m<sup>2</sup> by MDRD) with or without dialysis: Avoid administration. If the potential benefit of administration justifies the potential risk, monitor renal function and reduce the FOLOTYN dose based on adverse reactions [see *Warnings and Precautions (5.6), Use in Specific Populations (8.6)*].

#### **2.4 Monitoring and Dosage Modifications for Adverse Reactions**

##### Monitoring

Monitor complete blood cell counts and severity of mucositis at baseline and weekly. Perform serum chemistry tests, including renal and hepatic function, prior to the start of the first and fourth dose of each cycle.

##### Recommended Dosage Modifications

Do not administer FOLOTYN until:

- Mucositis Grade 1 or less.
- Platelet of 100,000/mcL or greater for first dose and 50,000/mcL or greater for all subsequent doses.
- Absolute neutrophil count (ANC) of 1,000/mcL or greater.

Dosage modifications for adverse reactions are provided in Tables 1, 2, and 3.

**Table 1 FOLOTYN Dose Modifications for Mucositis**

Mucositis Grade <sup>a</sup> on Day of Treatment	Action	Recommended Dose upon Recovery to Grade 0 or 1	
		Patients <u>Without</u> Severe Renal Impairment	Patients with Severe Renal Impairment
Grade 2	Omit dose	Continue prior dose	Continue prior dose
Grade 2 recurrence	Omit dose	20 mg/m <sup>2</sup>	10 mg/m <sup>2</sup>
Grade 3	Omit dose	20 mg/m <sup>2</sup>	10 mg/m <sup>2</sup>
Grade 4	Stop therapy		

<sup>a</sup> Based National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE version 3.0)

**Table 2 FOLOTYN Dosage Modifications for Myelosuppression**

Blood Count on Day of Treatment	Duration of Toxicity	Action	Recommended Dose Upon Recovery	
			Patients <u>Without</u> Severe Renal Impairment	Patients with Severe Renal Impairment
Platelet less than 50,000/mcL	1 week	Omit dose	Continue prior dose	Continue prior dose
	2 weeks	Omit dose	20 mg/m <sup>2</sup>	10 mg/m <sup>2</sup>

	3 weeks	Stop therapy		
ANC 500 to 1,000/mcL and no fever	1 week	Omit dose	Continue prior dose	Continue prior dose
ANC 500 to 1,000/mcL with fever or ANC less than 500/mcL	1 week	Omit dose, give G-CSF or GM-CSF	Continue prior dose with G-CSF or GM-CSF	Continue prior dose with G-CSF or GM-CSF support
	2 weeks or recurrence	Omit dose, give G-CSF or GM-CSF	20 mg/m <sup>2</sup> with G-CSF or GM-CSF	10 mg/m <sup>2</sup> with G-CSF or GM-CSF
	3 weeks or 2 <sup>nd</sup> recurrence	Stop therapy		

G-CSF=granulocyte colony-stimulating factor; GM-CSF=granulocyte macrophage colony-stimulating factor

**Table 3 FOLOTYN Dosage Modifications for All Other Adverse Reactions**

Toxicity Grade <sup>a</sup> on Day of Treatment	Action	Recommended Dose upon Recovery to Grade 2 or Lower	
		Patients <u>Without</u> Severe Renal Impairment	Patients with Severe Renal Impairment
Grade 3	Omit dose	20 mg/m <sup>2</sup>	10 mg/m <sup>2</sup>
Grade 4	Stop therapy		

<sup>a</sup> Based on NCI CTCAE version 3.0

## 2.5 Preparation and Administration

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Do not use any vials exhibiting particulate matter or discoloration.

FOLOTYN is a hazardous drug. Follow applicable special handling and disposal procedures.<sup>1</sup> If FOLOTYN comes in contact with the skin, immediately and thoroughly wash with soap and water. If FOLOTYN comes in contact with mucous membranes, flush thoroughly with water.

Aseptically withdraw the calculated dose from the appropriate number of vial(s) into a syringe for immediate use. Do not dilute FOLOTYN.

Administer undiluted FOLOTYN intravenously over 3-5 minutes via the side port of a free-flowing 0.9% Sodium Chloride Injection.

After withdrawal of dose, discard vial(s) including any unused portion.

### **3 DOSAGE FORMS AND STRENGTHS**

Injection: 40 mg/2 mL (20 mg/mL) and 20 mg/mL clear yellow sterile solution in single-dose vial

### **4 CONTRAINDICATIONS**

None

### **5 WARNINGS AND PRECAUTIONS**

#### **5.1 Myelosuppression**

FOLOTYN can cause myelosuppression, manifested by thrombocytopenia, neutropenia, and/or anemia.

Administer vitamin B<sub>12</sub> and instruct patients to take folic acid to reduce the risk of treatment-related myelosuppression [see *Dosage and Administration (2.1)*].

Monitor complete blood counts and omit and/or reduce the dose based on ANC and platelet count prior to each dose [see *Dosage and Administration (2.4)*].

#### **5.2 Mucositis**

FOLOTYN can cause mucositis [see *Adverse Reactions (6.1)*].

Administer vitamin B<sub>12</sub> and instruct patients to take folic acid to reduce the risk of mucositis [see *Dosage and Administration (2.1)*].

Monitor for mucositis weekly and omit and/or reduce the dose for grade 2 or higher mucositis [see *Dosage and Administration (2.4)*].

#### **5.3 Dermatologic Reactions**

FOLOTYN can cause severe dermatologic reactions, which may result in death. These dermatologic reactions have been reported in clinical studies (2.1% of 663 patients) and post marketing experience, and have included skin exfoliation, ulceration, and toxic epidermal necrolysis (TEN) [see *Adverse Reactions (6.1, 6.2)*]. They may be progressive and increase in severity with further treatment and may involve skin and subcutaneous sites of known lymphoma.

Monitor closely for dermatologic reactions. Withhold or discontinue FOLOTYN based on severity [see *Dosage and Administration (2.4)*].

#### **5.4 Tumor Lysis Syndrome**

FOLOTYN can cause tumor lysis syndrome (TLS). Monitor patients who are at increased risk of TLS and treat promptly.

#### **5.5 Hepatic Toxicity**

FOLOTYN can cause hepatic toxicity and liver function test abnormalities [see *Adverse Reactions (6.1)*]. Persistent liver function test abnormalities may be indicators of hepatic toxicity and require dose modification or discontinuation.

Monitor liver function tests. Omit dose until recovery, adjust or discontinue therapy based on the severity of the hepatic toxicity [see *Dosage and Administration (2.4)*].

#### **5.6 Risk of Increased Toxicity with Renal Impairment**

Patients with severe renal impairment (eGFR 15 to < 30 mL/min/1.73 m<sup>2</sup> based on MDRD) may be at greater risk for increased exposure and adverse reactions. Reduce FOLOTYN dosage in patients with severe renal impairment [see *Dosage and Administration (2.3)*].

Serious adverse reactions, including TEN and mucositis, were reported in patients with end stage renal disease (ESRD) undergoing dialysis who were administered FOLOTYN. Avoid FOLOTYN in patients with ESRD with or without dialysis. If the potential benefit of administration justifies the potential risk, monitor renal function and reduce the FOLOTYN dose based on adverse reactions [see *Dosage and Administration (2.3)*].

#### **5.7 Embryo-Fetal Toxicity**

Based on findings in animals and its mechanism of action, FOLOTYN can cause fetal harm when administered to a pregnant woman. FOLOTYN was embryotoxic and fetotoxic in rats and rabbits. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with FOLOTYN and for 6 months after the last dose. Advise males with female partners of reproductive potential to use effective contraception during treatment with FOLOTYN and for 3 months after the last dose [see *Use in Specific Populations (8.1, 8.3)*].

### **6 ADVERSE REACTIONS**

The following clinically significant adverse reactions are described elsewhere in the labeling:

- Myelosuppression [see *Warnings and Precautions (5.1)*]
- Mucositis [see *Warnings and Precautions (5.2)*]
- Dermatologic Reactions [see *Warnings and Precautions (5.3)*]
- Tumor Lysis Syndrome [see *Warnings and Precautions (5.4)*]
- Hepatic Toxicity [see *Warnings and Precautions (5.5)*]

#### **6.1 Clinical Trials Experience**

Because clinical studies are conducted under widely varying conditions, adverse reaction

rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.

### Peripheral T-cell Lymphoma

The safety of FOLOTYN was evaluated in Study PDX-008 [see *Clinical Studies (14)*]. Patients received FOLOTYN 30 mg/m<sup>2</sup> once weekly for 6 weeks in 7-week cycles. The median duration of treatment was 70 days (range: 1 day to 1.5 years). The majority of patients (69%, n = 77) remained at the target dose for the duration of treatment. Overall, 85% of scheduled doses were administered.

Forty-four percent of patients (n = 49) experienced a serious adverse event while on study or within 30 days after their last dose of FOLOTYN. The most common serious adverse events (> 3%), regardless of causality, were pyrexia, mucositis, sepsis, febrile neutropenia, dehydration, dyspnea, and thrombocytopenia. One death from cardiopulmonary arrest in a patient with mucositis and febrile neutropenia was reported in this trial. Across clinical trials, deaths from mucositis, febrile neutropenia, sepsis, and pancytopenia occurred in 1.2% of patients who received doses ranging from 30 mg/m<sup>2</sup> to 325 mg/m<sup>2</sup>.

Twenty-three percent of patients (n = 25) discontinued treatment with FOLOTYN due to adverse reactions. The most frequent adverse reactions reported as the reason for discontinuation of treatment were mucositis (6%) and thrombocytopenia (5%).

The most common adverse reactions (> 35%) were mucositis, thrombocytopenia, nausea, and fatigue.

Table 4 summarizes the adverse reactions in Study PDX-008.

**Table 4 Adverse Reactions in (≥ 10%) in Patients Who Received FOLOTYN in Study PDX-008**

	FOLOTYN N=111		
	All Grades (%)	Grade 3 (%)	Grade 4 (%)
Any Adverse Event	100	43	31
Mucositis <sup>a</sup>	70	17	4
Thrombocytopenia <sup>b</sup>	41	14	19 <sup>b</sup>
Nausea	40	4	0
Fatigue	36	5	2
Anemia	34	15	2
Constipation	33	0	0
Pyrexia	32	1	1
Edema	30	1	0
Cough	28	1	0
Epistaxis	26	0	0
Vomiting	25	2	0
Neutropenia	24	13	7
Diarrhea	21	2	0
Dyspnea	19	7	0
Hypokalemia	15	4	1

Anorexia	15	3	0
Rash	15	0	0
Pruritus	14	2	0
Pharyngolaryngeal pain	14	1	0
Liver function test abnormal <sup>c</sup>	13	5	0
Abdominal pain	12	4	0
Pain in extremity	12	0	0
Leukopenia	11	3	4
Back pain	11	3	0
Night sweats	11	0	0
Asthenia	10	1	0
Upper respiratory tract infection	10	1	0
Tachycardia	10	0	0

<sup>a</sup>Mucositis includes stomatitis or mucosal inflammation of the gastrointestinal and genitourinary tracts.

<sup>b</sup>Five patients with platelets < 10,000/mcL

<sup>c</sup>Liver function test abnormal includes increased ALT, increased AST, and increased transaminases

## 6.2 Postmarketing Experience

The following adverse reactions have been identified during postapproval use of FOLOTYN. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

*Dermatologic Reactions:* Toxic epidermal necrolysis.

## 7 DRUG INTERACTIONS

### 7.1 Effects of Other Drugs on FOLOTYN

Coadministration of FOLOTYN with probenecid increased pralatrexate plasma concentrations [see *Clinical Pharmacology (12.3)*], which may increase the risk of adverse reactions. Avoid coadministration with probenecid or nonsteroidal anti-inflammatory drugs. If coadministration is unavoidable, monitor for increased risk of adverse reactions.

## 8 USE IN SPECIFIC POPULATIONS

### 8.1 Pregnancy

#### Risk Summary

Based on findings from animal studies and its mechanism of action [see *Clinical Pharmacology (12.1)*], FOLOTYN can cause fetal harm when administered to a pregnant woman. There are insufficient data on FOLOTYN use in pregnant women to evaluate for a drug-associated risk. FOLOTYN was embryotoxic and fetotoxic in rats and rabbits when administered during organogenesis at doses about 1.2% (0.012 times) of the

clinical dose on a mg/m<sup>2</sup> basis. Advise pregnant women of the potential risk to a fetus.

The estimated background risk of major birth defects and miscarriage for the indicated population(s) is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.

## Data

### *Animal Data*

Pralatrexate was embryotoxic and fetotoxic in rats at intravenous doses of 0.06 mg/kg/day (0.36 mg/m<sup>2</sup>/day or about 1.2% of the clinical dose on a mg/m<sup>2</sup> basis) given on gestation days 7 through 20. Treatment with pralatrexate caused a dose-dependent decrease in fetal viability manifested as an increase in late, early, and total resorptions. There was also a dose-dependent increase in post-implantation loss. In rabbits, intravenous doses of 0.03 mg/kg/day (0.36 mg/m<sup>2</sup>/day) or greater given on gestation days 8 through 21 also caused abortion and fetal lethality. This toxicity manifested as early and total resorptions, post-implantation loss, and a decrease in the total number of live fetuses.

## **8.2 Lactation**

### Risk Summary

There is no data on the presence of pralatrexate in human milk or its effects on the breastfed child or milk production. Because of the potential for serious adverse reactions in a breastfed child, advise women not to breastfeed during treatment with FOLOTYN and for 1 week after the last dose.

## **8.3 Females and Males of Reproductive Potential**

FOLOTYN can cause fetal harm when administered to a pregnant woman [*see Use in Specific Populations (8.1)*].

### Pregnancy Testing

Verify pregnancy status in females of reproductive potential prior to initiation of FOLOTYN.

### Contraception

#### *Females*

Advise females of reproductive potential to use effective contraception during treatment with FOLOTYN and for 6 months following the last dose.

#### *Males*

Advise males with female partners of reproductive potential to use effective contraception during treatment with FOLOTYN and for 3 months following the last dose.

## **8.4 Pediatric Use**

The safety and effectiveness of FOLOTYN in pediatric patients have not been established.

## **8.5 Geriatric Use**

In the Study PDX-008, 36% of patients (n = 40) were 65 years of age and over. No overall differences in efficacy and safety were observed in patients based on age (< 65 years compared with ≥ 65 years). Due to the contribution of renal excretion to overall clearance of pralatrexate (approximately 34%), age-related decline in renal function may lead to a reduction in clearance and a commensurate increase in plasma exposure. In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. Since elderly patients may be at higher risk, monitor more closely. Omit dose and subsequently adjust or discontinue therapy for adverse reactions [see *Dosage and Administration (2.4)*].

## 8.6 Renal Impairment

No dosage modification is recommended for patients with mild or moderate renal impairment (eGFR 30 to 59 mL/min/1.73 m<sup>2</sup> based on MDRD). For patients with severe renal impairment (eGFR 15 to 29 mL/min/1.73 m<sup>2</sup>), reduce the recommended dose of FOLOTYN [see *Dosage and Administration (2.3)*].


Serious adverse drug reactions, including TEN and mucositis, have been reported in patients with ESRD undergoing dialysis. Avoid the use of FOLOTYN in patients with ESRD with or without dialysis. If the potential benefit of administration justifies the potential risk, monitor renal function and reduce the FOLOTYN dose based on adverse reactions [see *Dosage and Administration (2.3)*, *Warnings and Precautions (5.6)*].

## 10 OVERDOSAGE

No specific information is available on the treatment of overdose of FOLOTYN. If an overdose occurs, general supportive measures should be instituted as deemed necessary by the treating healthcare provider. Based on FOLOTYN's mechanism of action, consider the prompt administration of leucovorin.

## 11 DESCRIPTION

Pralatrexate is a dihydrofolate reductase inhibitor. Pralatrexate has the chemical name (2S)-2-[[4-[(1RS)-1-[(2, 4-diaminopteridin-6-yl)methyl]but-3-ynyl]benzoyl]amino]pentanedioic acid. The molecular formula is C<sub>23</sub>H<sub>23</sub>N<sub>7</sub>O<sub>5</sub> and the molecular weight is 477.48 g/mol. Pralatrexate is a 1:1 racemic mixture of S- and R-diastereomers at the C10 position (indicated with \*). The structural formula is as follows:



Pralatrexate is an off-white to yellow solid. It is soluble in aqueous solutions at pH 6.5 or higher. Pralatrexate is practically insoluble in chloroform and ethanol. The pKa values are 3.25, 4.76, and 6.17.

FOLOTYN (pralatrexate) is supplied as a preservative-free, sterile, isotonic, non-pyrogenic clear yellow aqueous solution contained in a clear glass single-dose vial (Type I) for intravenous use. Each 1 mL of solution contains 20 mg of pralatrexate, sufficient sodium chloride to achieve an isotonic (280-300 mOsm) solution, and sufficient sodium hydroxide, and hydrochloric acid if needed, to adjust and maintain the pH at 7.5-8.5. FOLOTYN is supplied as either 20 mg (1 mL) or 40 mg (2 mL) single-dose vials at a concentration of 20 mg/mL.

## **12 CLINICAL PHARMACOLOGY**

### **12.1 Mechanism of Action**

Pralatrexate is a folate analog metabolic inhibitor that competitively inhibits dihydrofolate reductase. It is also a competitive inhibitor for polyglutamylation by the enzyme folylpolyglutamyl synthetase. This inhibition results in the depletion of thymidine and other biological molecules the synthesis of which depends on single carbon transfer.

### **12.2 Pharmacodynamics**

Pralatrexate exposure-response relationship and the time course of pharmacodynamics responses are unknown.

### **12.3 Pharmacokinetics**

Pralatrexate is a racemic mixture of S- and R-diastereomers. The pharmacokinetics of pralatrexate at the recommended dosage of 30 mg/m<sup>2</sup> once weekly have been evaluated in 10 patients with PTCL. Pralatrexate total systemic exposure (AUC) and maximum plasma concentration (C<sub>max</sub>) increased proportionally over a dose range 30 to 325 mg/m<sup>2</sup> (10.8 times the approved recommended dosage). No accumulation of pralatrexate was observed.

#### Distribution

Steady-state volume of distribution of pralatrexate S- and R-diastereomers is 105 L and 37 L, respectively. Protein binding of pralatrexate is approximately 67% in vitro.

#### Elimination

The total systemic clearance of pralatrexate diastereomers was 417 mL/min (S-diastereomer) and 191 mL/min (R-diastereomer). The terminal elimination half-life of pralatrexate was 12-18 hours (coefficient of variance [CV] = 62-120%).

#### *Metabolism*

Pralatrexate is not significantly metabolized by CYP450 isozymes or glucuronidases in vitro.

#### *Excretion*

Following a single dose of FOLOTYN 30 mg/m<sup>2</sup>, approximately 34% of the pralatrexate dose was excreted unchanged into urine. Following a radiolabeled pralatrexate dose, 39% (CV = 28%) of the dose was recovered in urine as unchanged pralatrexate and 34% (CV = 88%) in feces as unchanged pralatrexate and/or any metabolites. 10% (CV =

95%) of the dose was exhaled over 24 hours.

#### Specific Populations

No clinically meaningful effect on the pharmacokinetics of pralatrexate was observed based on sex. The effect of hepatic impairment on the pharmacokinetics of pralatrexate has not been studied.

#### *Patients with Renal Impairment*

Following administration of a single dose of FOLOTYN, mean exposures of the pralatrexate S-diastereomer and R- diastereomer were comparable in patients with mild to moderate (eGFR 30 to 59 mL/min/1.73 m<sup>2</sup> based on MDRD) renal impairment as compared with severe (eGFR 15 to 29 mL/min/1.73 m<sup>2</sup>) renal impairment. The mean fraction of the administered dose excreted as unchanged diastereomers in urine ( $f_e$ ) decreased with declining renal function [see *Use in Specific Populations (8.6)*].

#### Drug Interaction Studies

##### *Clinical Studies*

Coadministration of probenecid (an inhibitor of multidrug resistance-associated protein 2 [MRP2] in vitro) resulted in delayed clearance of pralatrexate.

##### *In Vitro Studies*

*Cytochrome P450 (CYP) Enzymes:* Pralatrexate does not induce or inhibit CYP enzymes.

*Transporter Systems:* Pralatrexate is a substrate for BCRP, MRP2, MRP3, and OATP1B3, but is not a substrate of P-gp, OATP1B1, OCT2, OAT1, or OAT3.

Pralatrexate inhibits MRP2 and MRP3, but does not inhibit P-gp, BCRP, OCT2, OAT1, OAT3, OATP1B1, or OATP1B3. MRP3 is a transporter that may affect the transport of etoposide and teniposide.

## **13 NONCLINICAL TOXICOLOGY**

### **13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility**

#### Carcinogenesis

Carcinogenicity studies have not been performed with pralatrexate.

#### Mutagenesis

Pralatrexate did not cause mutations in the Ames test or the Chinese hamster ovary cell chromosome aberration assay. Nevertheless, these tests do not reliably predict genotoxicity for this class of compounds. Pralatrexate did not cause mutations in the mouse micronucleus assay.

#### Impairment of Fertility

No fertility studies have been performed.

## **14 CLINICAL STUDIES**

The efficacy of FOLOTYN was evaluated in Study PDX-008, an open-label, single-arm, multi-center, international trial that enrolled patients with relapsed or refractory PTCL. One hundred and eleven patients received FOLOTYN 30 mg/m<sup>2</sup> intravenously over 3 to 5 minutes once weekly for 6 weeks in 7-week cycles until disease progression or

unacceptable toxicity. Of the 111 patients treated, 109 patients were evaluable for efficacy. Evaluable patients had histologically confirmed PTCL by independent central review using the Revised European American Lymphoma (REAL) World Health Organization (WHO) disease classification, and relapsed or refractory disease after at least one prior treatment.

The major efficacy outcome measure was overall response rate (complete response, complete response unconfirmed, and partial response) as assessed by International Workshop Criteria (IWC). An additional efficacy outcome measure was duration of response. Response assessments were scheduled at the end of cycle 1 and then every other cycle (every 14 weeks). Duration of response was measured from the first day of documented response to disease progression or death. Response and disease progression were evaluated by independent central review using the IWC.

The median age was 59 years (range: 21 to 85); 68% were male; 72% were White, 13% were Black, 8% were Hispanic and 5% were Asian. Patients had a baseline Eastern Cooperative Oncology Group (ECOG) performance status of 0 (39%), 1 (44%), or 2 (17%). The median time from initial diagnosis to study entry was 1.3 years (range 24 days to 26.8 years). The median number of prior systemic therapies was 3 (range 1 to 12). Approximately 24% of patients (n = 27) did not have evidence of response to any previous therapy. Approximately 63% of patients (n = 70) did not have evidence of response to their most recent prior therapy before entering the study.

Efficacy results are provided in Table 5.

**Table 5 Efficacy Results for Study PDX-008 per Independent Central Review (IWC)**

	<b>Evaluable Patients (N=109)</b>		<b>Median Duration of Response</b>	<b>Range of Duration of Response</b>
	<b>N (%)</b>	<b>95% CI</b>		
<b>Overall Response</b>				
CR+CRu+PR	29 (27)	19, 36	287 days (9.4 months)	1-503 days
CR/CRu	9 (8)			
PR	20 (18)			
<b>Responses ≥ 14 weeks</b>				
CR+CRu+PR	13 (12)	7, 20	Not Reached	98-503 days
CR/CRu	7 (6)			
PR	6 (6)			

Fourteen patients went off treatment in cycle 1; 2 patients were unevaluable for response by IWC due to insufficient materials provided to central review.

CR = Complete Response, CRu = Complete Response unconfirmed, PR = Partial Response

The initial response assessment was scheduled at the end of cycle 1. Of the responders, 66% responded within cycle 1. The median time to first response was 45 days (range 37-349 days).

## 15 REFERENCES

1. "OSHA Hazardous Drugs." OSHA.  
<http://www.osha.gov/SLTC/hazardousdrugs/index.html>.

## 16 HOW SUPPLIED/STORAGE AND HANDLING

FOLOTYN is available in clear glass single-dose vials containing pralatrexate at a concentration of 20 mg/mL as a preservative-free, sterile, clear yellow solution individually packaged for intravenous use in the following presentations:

**NDC 72893-003-01:** 20 mg of pralatrexate in 1 mL solution in a vial (20 mg / 1 mL)

**NDC 72893-005-01:** 40 mg of pralatrexate in 2 mL solution in a vial (40 mg / 2 mL)

Store refrigerated at 2-8°C (36-46°F) [see USP Controlled Cold Temperature] in original carton to protect from light.

FOLOTYN is a hazardous drug. Follow applicable special handling and disposal procedures.<sup>1</sup>

## 17 PATIENT COUNSELING INFORMATION

Advise the patient to read the FDA-approved patient labeling (Patient Information).

### Folic Acid and Vitamin B<sub>12</sub> Supplementation

Advise patients treated with FOLOTYN to take folic acid and vitamin B<sub>12</sub> to reduce the risk of possible side effects [see *Dosage and Administration (2.1)*].

### Myelosuppression

Inform patients of the risk of myelosuppression and to immediately contact their healthcare provider should any signs of infection develop, including fever. Inform patients to contact their healthcare provider if bleeding or symptoms of anemia occur [see *Warnings and Precautions (5.1)*].

### Mucositis

Inform patients of the signs and symptoms of mucositis. Instruct patients on ways to reduce the risk of its development, and on ways to maintain nutrition and control discomfort from mucositis if it occurs [see *Warnings and Precautions (5.2)*].

### Dermatologic Reactions

Advise patients about the risks for and the signs and symptoms of dermatologic reactions. Instruct patients to immediately notify their healthcare provider if any skin reactions occur [see *Warnings and Precautions (5.3)*].

### Tumor Lysis Syndrome

Inform patients about the risk of and the signs and symptoms of tumor lysis syndrome. Patients should be instructed to notify their healthcare provider if they experience these symptoms [see *Warnings and Precautions (5.4)*].

### Concomitant Medications

Patients should be instructed to inform their healthcare provider if they are taking any concomitant medications including prescription drugs (such as trimethoprim/sulfamethoxazole and probenecid) and nonprescription drugs (such as nonsteroidal anti-inflammatory drugs) [see *Drug Interactions (7.1)*].

### Embryo-Fetal Toxicity

Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females of reproductive potential to inform their healthcare provider of a known or suspected pregnancy [see *Warnings and Precautions (5.7) and Use in Specific Populations (8.1)*].

Advise females patients of reproductive potential to use effective contraception during treatment with FOLOTYN and for 6 months after the final dose [see *Use in Specific Populations (8.3)*].

Advise males with female partners of reproductive potential to use effective contraception during treatment with FOLOTYN and for at least 3 months after the final dose [see *Use in Specific Populations (8.3)*]

### Lactation

Advise females women not to breastfeed during treatment with FOLOTYN and for 1 week after the final dose [see *Use in Specific Populations (8.2)*].

Manufactured by:  
Baxter Oncology GmbH  
Halle, 33790, Germany

Manufactured for:  
Acrotech Biopharma Inc  
East Windsor, NJ 08520 USA  
1-888-255-6788  
FOLOTYN is a registered trademark of Acrotech Biopharma Inc. U.S.

Patents: 6,028,071, 7,622,470 and 8,299,078  
© Acrotech Biopharma Inc. All rights reserved.

## **SPL PATIENT PACKAGE INSERT SECTION**

### **Patient Information**

#### **FOLOTYN® (FOH-loh-tin) (pralatrexate injection)**

#### **What is FOLOTYN?**

FOLOTYN is a prescription used to treat people with a type of cancer called peripheral T-cell lymphoma (PTCL) that does not go away, gets worse, or comes back after use of another cancer treatment. It is not known if FOLOTYN is safe and effective in children.

#### **Before you receive FOLOTYN, tell your healthcare provider about all of your medical conditions, including if you:**

- have kidney problems, including end-stage renal disease (ESRD)
- are pregnant or plan to become pregnant. FOLOTYN can harm your unborn baby.

#### **Females who are able to become pregnant:**

- Your healthcare provider may do a pregnancy test before you start treatment

with FOLOTYN.

- You should use effective birth control (contraception) during treatment with FOLOTYN and for 6 months after the last dose. Talk to your healthcare provider about the best birth control methods you can use during this time.
- Tell your healthcare provider if you become pregnant or think you may be pregnant during treatment with FOLOTYN.

**Males with female partners who are able to become pregnant** should use effective birth control during treatment with FOLOTYN and for 3 months after the last dose of FOLOTYN.

- are breastfeeding or plan to breastfeed. It is not known if FOLOTYN passes into your breast milk. Do not breastfeed during treatment with FOLOTYN and for 1 week after the last dose. Talk to your healthcare provider about the best way to feed your baby during treatment with FOLOTYN.

**Tell your healthcare provider about all the medicines you take**, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Some medicines may affect how FOLOTYN works.

Especially tell your healthcare provider if you take:

- sulfamethoxazole trimethoprim
- non-steroidal anti-inflammatory drugs (NSAIDs) medicines
- probenecid

Know the medicines you take. Keep a list of them and show it to your healthcare provider or pharmacist each time you start a new medicine.

### **How will I receive FOLOTYN?**

- FOLOTYN will be given to you by your healthcare provider as an intravenous (IV) injection into your vein over 3 to 5 minutes.
- FOLOTYN is usually given in cycles, one time each week for 6 weeks, with no treatment on the 7th week.
- **Your healthcare provider will treat you with folic acid and vitamin B12 before and during your treatment with FOLOTYN to help reduce the risk of possible side effects.**
  - You will take folic acid by mouth for 10 days before your first dose of FOLOTYN. Continue taking folic acid during treatment with FOLOTYN and for 30 days after the last dose.
  - Your healthcare provider will give you a vitamin B12 injection into your muscle (intramuscular). You will get your first vitamin B12 injection 10 weeks before your first dose of FOLOTYN and every 8 to 10 weeks during treatment with FOLOTYN.
- Your healthcare provider will do blood tests before and during treatment with FOLOTYN.

Your healthcare provider may stop treatment, delay treatment, or change your dose of FOLOTYN based on results of your blood tests and if you have certain side effects.

### **What are the possible side effects of FOLOTYN?**

**FOLOTYN may cause serious side effects, including:**

- **Low blood cell counts:** Your healthcare provider will do blood tests to check your blood cell counts before and during treatment with FOLOTYN. **Tell your healthcare provider right away if you develop any signs of infection, fever, bleeding or tiredness during treatment with FOLOTYN.**
- **Redness and sores of the mucous membrane lining of the mouth, lips, throat, digestive tract, and genitals (mucositis).** Mucositis is common with FOLOTYN and can be severe. Tell your healthcare provider if you develop redness or painful sores in your mouth or throat, or have trouble speaking, eating or drinking. Your healthcare provider will tell you about ways to reduce your risk of getting mucositis, and how to maintain nutrition and help control the discomfort from mucositis.
- **Severe skin reactions.** FOLOTYN can cause severe skin reactions that may lead to death. In people with lymphoma, severe skin reactions may happen on and under your skin. Tell your healthcare provider right away if you develop any of the following skin reactions:
  - rash
  - peeling and loss of skin
  - sores
  - blisters
- **Tumor Lysis Syndrome (TLS).** TLS is caused by the fast breakdown of certain types of cancer cells. Your healthcare provider may do blood tests to check you for TLS and treat you if needed.
- **Liver problems.** Your healthcare provider will monitor you for liver problems during treatment with FOLOTYN.
- **Increased risk of serious reactions in people with kidney problems.** People with severe kidney problems may have a greater risk for increased serious reactions during treatment with FOLOTYN.

**The most common side effects of FOLOTYN include:** low platelet blood counts, nausea, and tiredness.

These are not all of the possible side effects of FOLOTYN.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

**General information about the safe and effective use of FOLOTYN.**

Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. This Patient Information leaflet summarizes the most important information about FOLOTYN. If you would like more information, talk with your healthcare provider. You can ask your healthcare provider or pharmacist for information about FOLOTYN that is written for health professionals.

**What are the ingredients in FOLOTYN?**

**Active ingredient:**pralatrexate

**Inactive ingredients:**sodium chloride, sodium hydroxide, and hydrochloric acid

Manufactured by:  
Baxter Oncology GmbH  
Halle, 33790, Germany

Manufactured for:

Acrotech Biopharma Inc  
East Windsor, NJ 08520 USA

FOLOTYN and the flower symbol are all registered trademarks of Acrotech Biopharma Inc.



© Acrotech Biopharma Inc. All rights reserved.

For more information, go to [www.FOLOTYN.com](http://www.FOLOTYN.com) or call 1-888-255-6788.

This Patient Information has been approved by the U.S. Food and Drug Administration  
Revised: Jun2023

**PACKAGE LABEL.PRINCIPAL DISPLAY PANEL**

**PACKAGE CARTON - FOLOTYN 20 mg/1 mL Vial**

NDC 72893-003-01

FOLOTYN®


(pralatrexate injection)

20 mg/mL

For intravenous use

Rx only

1 mL



**PACKAGE LABEL.PRINCIPAL DISPLAY PANEL**

**PACKAGE CARTON - FOLOTYN 40 mg/2 mL Vial**

NDC 72893-005-01

FOLOTYN®

(pralatrexate injection)


40 mg/2 mL

(20 mg/mL)

For intravenous use

Rx only

2 mL



## PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

### VIAL - FOLOTYN 20 mg/1 ml

NDC 72893-003-01


FOLOTYN®

(pralatrexate injection)

20 mg/mL

Rx only

1 mL



**PACKAGE LABEL.PRINCIPAL DISPLAY PANEL**

**VIAL - FOLOTYN 40 mg/2 ml**

NDC 72893-005-01


FOLOTYN®

(pralatrexate injection)

40 mg/2 mL  
(20 mg/mL)

Rx only

2 mL



## FOLOTYN

pralatrexate injection

### Product Information

<b>Product Type</b>	HUMAN PRESCRIPTION DRUG	<b>Item Code (Source)</b>	NDC:72893-003
<b>Route of Administration</b>	INTRAVENOUS		

### Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
PRALATREXATE (UNII: A8Q819Q20) (PRALATREXATE - UNII:A8Q819Q20)	PRALATREXATE	20 mg in 1 mL

### Inactive Ingredients

Ingredient Name	Strength
SODIUM CHLORIDE (UNII: 451W47IQ8X)	
SODIUM HYDROXIDE (UNII: 55X04QC32I)	
HYDROCHLORIC ACID (UNII: QTT17582CB)	
WATER (UNII: 059QF0KO0R)	

### Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:72893-003-01	1 in 1 CARTON	09/24/2009	

1	1 mL in 1 VIAL; Type 0: Not a Combination Product		
<b>Marketing Information</b>			
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
NDA	NDA022468	09/24/2009	

**FOLOTYN**  
pralatrexate injection

<b>Product Information</b>			
Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:72893-005
Route of Administration	INTRAVENOUS		

<b>Active Ingredient/Active Moiety</b>			
Ingredient Name	Basis of Strength	Strength	
PRALATREXATE (UNII: A8Q8I19Q20) (PRALATREXATE - UNII:A8Q8I19Q20)	PRALATREXATE	40 mg in 2 mL	

<b>Inactive Ingredients</b>			
Ingredient Name	Strength		
SODIUM CHLORIDE (UNII: 451W47IQ8X)			
SODIUM HYDROXIDE (UNII: 55X04QC32I)			
HYDROCHLORIC ACID (UNII: QTT17582CB)			
WATER (UNII: 059QF0KO0R)			

<b>Packaging</b>				
#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:72893-005-01	1 in 1 CARTON	09/24/2009	
1		2 mL in 1 VIAL; Type 0: Not a Combination Product		

<b>Marketing Information</b>			
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
NDA	NDA022468	09/24/2009	

**Labeler** - Acrotech Biopharma Inc (116965616)

**Registrant** - Acrotech Biopharma Inc (116965616)

**Establishment**

<b>Name</b>	<b>Address</b>	<b>ID/FEI</b>	<b>Business Operations</b>
Baxter Oncology, GmbH, (Baxter)		344276063	MANUFACTURE(72893-003, 72893-005)

Revised: 6/2023

Acrotech Biopharma Inc